Endocrine therapy after breast-conserving surgery may be the only treatment needed in patients aged ≥55 years with low-grade luminal type A breast cancer, sparing them radiation therapy, including its side effects, financial burden, and inconvenience, according to findings from the single-arm LUMINA clinical trial reported at the 2022 American Society of Clinical Oncology Annual Meeting. Read More ›

Several baseline factors were associated with an increased risk for early treatment discontinuation in the phase 3 monarchE clinical trial, which assessed adjuvant abemaciclib (Verzenio) in patients with hormone receptor–positive, HER2-negative early breast cancer, according to findings from a multivariate analysis presented during the 2022 American Society of Clinical Oncology Annual Meeting. Read More ›

Targeting HER2 with the antibody–drug conjugate fam-trastuzumab deruxtecan-nxki (Enhertu; T-DXd) provided clinically meaningful benefits for patients with HER2-low metastatic breast cancer, according to findings presented at the 2022 American Society of Clinical Oncology Annual Meeting. Read More ›

The investigational oral selective estrogen receptor degrader (SERD) elacestrant (RAD1901) significantly reduced the risk for death or disease progression and improved progression-free survival (PFS) compared with standard-of-care (SOC) endocrine therapy in patients with estrogen receptor (ER)-positive, HER2-negative metastatic breast cancer who had progressed on prior endocrine and targeted therapies, according to results of the phase 3 EMERALD clinical trial. Read More ›

Second-line therapy with trastuzumab deruxtecan (Enhertu; T-DXd) extended progression-free survival (PFS) and improved objective response rate (ORR) versus trastuzumab emtansine (Kadcyla; T-DM1) in women with HER2-positive metastatic breast cancer, including those with stable brain metastasis at baseline, according to a subgroup analysis of a phase 3 clinical trial. Read More ›

The phase 3 OlympiA trial showed olaparib had impressive results versus placebo, with improvement in disease-free survival with adjuvant olaparib in early-stage, HER2-negative breast cancer and BRCA1/2 mutations. This highlights the need to test for BRCA1/2 mutations to determine if patients qualify for olaparib. Read More ›

A recent study found that omega-6 PUFA supplementation surprisingly reduced cancer-related fatigue in exhausted American breast cancer survivors when compared with omega-3 PUFA supplementation, and that omega-6 PUFA supplementation surprisingly lowered proinflammatory blood markers, completely against expectations. Read More ›

Results of a recent web-based survey show that survey respondents are in favor of several changes in breast cancer treatment during COVID-19. These changes must be discussed on a local level, taking into consideration the infrastructure and resources available. Read More ›

Page 1 of 28

Subscribe Today!

To sign up for our newsletter or print publications, please enter your contact information below.

I'd like to receive: